Cumberland Pharmaceuticals (Nashville, Tenn) recently received FDA approval for revised labeling for Acetadote Injection. The product is used in an emergency room setting to prevent or lessen potential liver damage resulting from an overdose of acetaminophen, a common ingredient in many OTC painkillers. Acetadote, administered intravenously within 8 to 10 hours after ingestion of a potentially hepatotoxic quantity of acetaminophen, is indicated to prevent or lessen hepatic injury. The revised package insert includes a dosage guide for pediatric patients who weigh <40 kg. The loading dose (300 mg/kg) administration also has been extended to 60 minutes, making the total recommended treatment time 21 hours. Acetadote is available as a 20% solution in 30-mL (200 mg/mL) single-dose vials. For more information, visit www.acetadote.com, or call 877-484-2700.